Pharmaceuticals

Future Demand and Leading Companies Shaping the Pharmaceutical Supply Chain Management Market to 2029

September 1, 2025 by Marketing Posting

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_

_x000D_

#What Is the Outlook for the Pharmaceutical Supply Chain Management Market Heading Into 2029?#_x000D_

The market for calcineurin inhibitors has seen considerable expansion in the past few years. It is projected to increase from $8.84 billion in 2024 to $9.49 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.4%. The growth during the historical period can be credited to quicker regulatory approvals for immunosuppressants, advantageous reimbursement policies for transplant medications, heightened government backing for organ transplantation, the development of the healthcare infrastructure, along with the rise of specialty pharmacies dealing in immunosuppressants._x000D_

_x000D_

The market size for calcineurin inhibitors is predicted to experience substantial expansion in the upcoming years, increasing to “$12.8 billion in 2029 with a compound annual growth rate (CAGR) of 7.8%. The predicted escalation during the forecast period can be associated with the rising occurrences of autoimmune ailments, growing cases of chronic kidney diseases necessitating transplants, increasing incidents of atopic dermatitis and psoriasis, and the expanding demographic requiring immunosuppressive treatments. Notable trends for the forecast duration encompass progress in drug formulations for enhanced efficiency, the creation of extended-release formulations, studies on combination treatments involving calcineurin inhibitors, breakthroughs in drug delivery techniques and a deepened comprehension of t-cell signaling pathways._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=23336&type=smp_x000D_

_x000D_

#Which Factors Are Pushing The Pharmaceutical Supply Chain Management Market Forward?#_x000D_

The rising need for pharmaceutical goods is set to boost the expansion of the pharmaceutical supply chain management market in the future. Pharmaceutical items, which include medications and drugs created and distributed to combat, prevent or manage various health issues and diseases, depend on the pharmaceutical supply chain management for their effective production, distribution and surveillance, thus ensuring prompt availability of necessary healthcare products. As illustrated by the European Federation of Pharmaceutical Industries and Associations, a Belgium-based industry association and advocacy group, the value of pharmaceuticals manufactured in Europe skyrocketed from 347.31 billion USD (323,950 million euros) in 2021 to 364.26 billion USD (340,000 million euros) in 2022, as of June 2023 marking a jump of 4.88%. Consequently, the escalating requirement for pharmaceutical goods will fuel the expansion of the pharmaceutical supply chain management market._x000D_

_x000D_

The calcineurin inhibitors market covered in this report is segmented – _x000D_

_x000D_

1) By Product: Branded, Generic_x000D_

2) By Dosage: Tablets And Capsules, Ointments, Injections, Other Dosages_x000D_

3) By Indication: Organ Transplantation, Autoimmune Disease, Other Indications_x000D_

4) By End User: Hospitals, Homecare Settings, Pharmacies_x000D_

_x000D_

Subsegments:_x000D_

1) By Branded: Patented Drugs, Proprietary Formulations_x000D_

2) By Generic: Off-Patent Equivalents, Biosimilars_x000D_

_x000D_

#Which Trends Are Redefining The Future Landscape Of The Pharmaceutical Supply Chain Management Industry?#_x000D_

Leading corporations involved in the calcineurin inhibitors market are placing emphasis on the development of immunosuppressant treatments, such as drugs designed specifically for autoimmune conditions. This approach is geared towards managing overactive immune reactions, alleviating inflammation, and guarding against tissue destruction. Autoimmune disease medication essentially modulates the immune system by suppressing hyperactive immune reactions or adjusting the immune functionality to lessen inflammation and tissue harm, integrating corticosteroids, immunosuppressants, biologics, and disease-modifying antirheumatic drugs (DMARDs). For example, in April 2024, the South African Health Products Regulatory Authority (SAHPRA) granted Biocon Limited, a biopharmaceutical manufacturer based in India, the approval for Tacrolimus. A calcineurin inhibitor and immunosuppressant, Tacrolimus is utilized to ward off organ rejection in those who have had transplants. Having been extensively employed in renal transplant scenarios for over twenty years thanks to its effectiveness, Tacrolimus operates by integrating with the immunophilin FKBP-12, establishing a complex that obstructs calcineurin action. This blocking ultimately prevents NF-AT dephosphorylation, leading to a decline in interleukin-2 (IL-2) output and T-cell growth, both of which are integral to the immune opposition to transplanted organs._x000D_

_x000D_

#Which Organizations Are Driving Progress In The Pharmaceutical Supply Chain Management Industry?#_x000D_

Major companies operating in the calcineurin inhibitors market are Pfizer Inc., Roche Holding AG, Bristol-Myers Squibb Company, Novartis AG, Viatris Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Huadong Medicine Co. Ltd., Sun Pharmaceutical Industries Ltd., Apotex Inc., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Lupin Pharmaceutical Inc., Zydus Cadila, Biocon Limited, Glenmark Pharmaceuticals Ltd., Accord Healthcare Ltd., Strides Pharma Science Limited, Harrow Inc., Panacea Biotec Ltd. _x000D_

_x000D_

https://www.thebusinessresearchcompany.com/report/calcineurin-inhibitors-global-market-report_x000D_

_x000D_

#Which Region Is Expected To Experience The Highest Growth In The Pharmaceutical Supply Chain Management Industry?#_x000D_

North America was the largest region in the calcineurin inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the calcineurin inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=23336&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_